JP2014509657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509657A5 JP2014509657A5 JP2014502871A JP2014502871A JP2014509657A5 JP 2014509657 A5 JP2014509657 A5 JP 2014509657A5 JP 2014502871 A JP2014502871 A JP 2014502871A JP 2014502871 A JP2014502871 A JP 2014502871A JP 2014509657 A5 JP2014509657 A5 JP 2014509657A5
- Authority
- JP
- Japan
- Prior art keywords
- vemurafenib
- acceptable salt
- pharmaceutically acceptable
- compound
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 44
- 229960003862 vemurafenib Drugs 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 31
- 201000001441 melanoma Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 7
- 102200055464 rs113488022 Human genes 0.000 claims description 7
- 238000009097 single-agent therapy Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 18
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 229960003668 docetaxel Drugs 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940034727 zelboraf Drugs 0.000 description 2
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000034331 Squamous cell carcinoma of the stomach Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000000496 gastric squamous cell carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000036907 triple-positive breast carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470624P | 2011-04-01 | 2011-04-01 | |
| US201161470803P | 2011-04-01 | 2011-04-01 | |
| US61/470,803 | 2011-04-01 | ||
| US61/470,624 | 2011-04-01 | ||
| PCT/US2012/031665 WO2012135750A1 (en) | 2011-04-01 | 2012-03-30 | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509657A JP2014509657A (ja) | 2014-04-21 |
| JP2014509657A5 true JP2014509657A5 (OSRAM) | 2016-09-15 |
| JP6143739B2 JP6143739B2 (ja) | 2017-06-07 |
Family
ID=46931958
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502876A Active JP6239497B2 (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法 |
| JP2014502873A Pending JP2014512354A (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法 |
| JP2014502886A Pending JP2014512356A (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及び化学療法剤の組み合わせ、及び使用方法 |
| JP2014502871A Active JP6143739B2 (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及びベムラフェニブの組み合わせ、及び使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502876A Active JP6239497B2 (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法 |
| JP2014502873A Pending JP2014512354A (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法 |
| JP2014502886A Pending JP2014512356A (ja) | 2011-04-01 | 2012-03-30 | Ａｋｔ阻害剤化合物及び化学療法剤の組み合わせ、及び使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US20150064171A1 (OSRAM) |
| EP (4) | EP2694072B2 (OSRAM) |
| JP (4) | JP6239497B2 (OSRAM) |
| KR (4) | KR20140025434A (OSRAM) |
| CN (8) | CN103874689B (OSRAM) |
| AU (4) | AU2012236144B2 (OSRAM) |
| BR (4) | BR112013025353A8 (OSRAM) |
| CA (4) | CA2831922C (OSRAM) |
| DK (1) | DK2694072T4 (OSRAM) |
| ES (3) | ES2620644T3 (OSRAM) |
| FI (1) | FI2694072T4 (OSRAM) |
| HK (1) | HK1204575A1 (OSRAM) |
| HR (1) | HRP20180223T4 (OSRAM) |
| HU (1) | HUE036513T2 (OSRAM) |
| IL (4) | IL228642A0 (OSRAM) |
| LT (1) | LT2694072T (OSRAM) |
| ME (1) | ME02998B (OSRAM) |
| MX (4) | MX2013011329A (OSRAM) |
| MY (1) | MY179607A (OSRAM) |
| PL (2) | PL2694485T3 (OSRAM) |
| PT (1) | PT2694072T (OSRAM) |
| RS (1) | RS56759B2 (OSRAM) |
| RU (4) | RU2013148721A (OSRAM) |
| SG (5) | SG10201504303SA (OSRAM) |
| SI (1) | SI2694072T2 (OSRAM) |
| SM (1) | SMT201800250T1 (OSRAM) |
| TR (1) | TR201802093T4 (OSRAM) |
| WO (4) | WO2012135759A1 (OSRAM) |
| ZA (4) | ZA201308064B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX358640B (es) | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| HUE060249T2 (hu) | 2008-06-16 | 2023-02-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| TWI546305B (zh) | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| MX356704B (es) | 2011-01-11 | 2018-06-11 | Novartis Ag | Combinación. |
| CA2831922C (en) | 2011-04-01 | 2019-12-31 | Genentech, Inc. | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20150023954A1 (en) * | 2012-03-23 | 2015-01-22 | Memorial Sloan-Kettering Cancer Center | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
| CA2904338C (en) * | 2013-03-05 | 2022-07-05 | University Of Tennessee Research Foundation | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer |
| CN103304404B (zh) * | 2013-05-30 | 2015-07-29 | 万华化学集团股份有限公司 | 一种2,2-二羟甲基丁酸的制备方法 |
| EP3718544A1 (en) * | 2013-10-01 | 2020-10-07 | Novartis AG | Combination |
| CN105899492B (zh) * | 2013-11-15 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 用于制备嘧啶基环戊烷化合物的方法 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3164129A1 (en) * | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| KR101689542B1 (ko) | 2015-01-15 | 2016-12-26 | 숭실대학교산학협력단 | 폐암치료 향상을 위한 제피티닙 또는 에를로티닙 나노복합체 |
| EP3072528B1 (en) * | 2015-03-26 | 2017-07-05 | ratiopharm GmbH | Composition comprising vemurafenib and cationic copolymer based on methacrylates |
| EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| WO2017095826A1 (en) * | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
| WO2017120218A1 (en) * | 2016-01-04 | 2017-07-13 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of prostate cancer cells with fat oxidation inhibitors and enzalutamide |
| WO2017176423A1 (en) * | 2016-04-08 | 2017-10-12 | Biodesix, Inc. | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3807248A4 (en) * | 2018-05-29 | 2021-10-27 | Council of Scientific and Industrial Research | BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE |
| CN113194941A (zh) | 2018-12-19 | 2021-07-30 | 基因泰克公司 | 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌 |
| JP7667132B2 (ja) * | 2019-08-12 | 2025-04-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
| WO2021118664A1 (en) | 2019-09-13 | 2021-06-17 | Praxair S.T. Technology, Inc. | Methods for producing increased crystalline and dense improved coatings |
| EP4153174A4 (en) * | 2020-05-19 | 2024-10-09 | Board of Regents, The University of Texas System | METHODS FOR THE TREATMENT OF PANCREATITIS AND PREVENTION OF PANCREAS CANCER |
| CN117677614A (zh) * | 2021-12-17 | 2024-03-08 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US729332A (en) * | 1902-07-21 | 1903-05-26 | Frank C Guss | Animal catching and holding device. |
| US2885396A (en) | 1957-03-21 | 1959-05-05 | Heidelberger Charles | N-glycosides of 5-fluorouracil |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3885035A (en) | 1972-04-05 | 1975-05-20 | Sandoz Ag | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines |
| CH588505A5 (OSRAM) | 1972-06-08 | 1977-06-15 | Research Corp | |
| US3956495A (en) | 1973-10-30 | 1976-05-11 | Eli Lilly And Company | 2,4-Diaminoquinazolines as antithrombotic agents |
| US3966936A (en) | 1974-02-21 | 1976-06-29 | Pfizer Inc. | Piperazino quinazoline bronchodilators |
| US4060615A (en) | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| JPS562968A (en) | 1979-06-21 | 1981-01-13 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
| US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| JPS6270A (ja) | 1985-03-07 | 1987-01-06 | Sankyo Co Ltd | シクロペンタ〔ｄ〕ピリミジン誘導体 |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| WO1987004928A1 (fr) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4889856A (en) | 1987-08-31 | 1989-12-26 | Merck & Co., Inc. | 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers |
| US4871739A (en) | 1987-01-21 | 1989-10-03 | Merck & Co., Inc. | Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents |
| US4994464A (en) | 1987-08-31 | 1991-02-19 | Merck & Co., Inc. | Piperazinylpyrimidines as β-adrenergic receptor blockers |
| WO1990007926A1 (en) | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| DK0664291T3 (da) | 1992-10-05 | 2000-10-30 | Ube Industries | Pyrimidinforbindelse |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US5750545A (en) | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US7294332B2 (en) * | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| JP2002511092A (ja) | 1997-07-01 | 2002-04-09 | ワーナー−ランバート・コンパニー | ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用 |
| US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| ES2356886T3 (es) | 1998-03-31 | 2011-04-14 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1140067A1 (en) | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
| EP1144371B1 (en) | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
| AP2001002225A0 (en) | 1999-01-13 | 2001-09-30 | Warner Lambert Co | 1-heterocycle substituted diarylamines. |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| US9534254B1 (en) | 1999-02-02 | 2017-01-03 | Abbott Molecular Inc. | Patient stratification for cancer therapy based on genomic DNA microarray analysis |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| ATE377597T1 (de) | 1999-07-09 | 2007-11-15 | Glaxo Group Ltd | Anilinochinazoline als protein-tyrosin- kinasehemmer |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| HUP0202381A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| AU5786000A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| AU7307101A (en) | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| IL153817A0 (en) | 2000-07-19 | 2003-07-31 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| MXPA03001654A (es) | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| AU2001296871A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
| WO2002056912A2 (en) | 2001-01-16 | 2002-07-25 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| DE60225127T2 (de) | 2001-04-30 | 2009-02-19 | Glaxo Group Ltd., Greenford | Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf) |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| JP4391825B2 (ja) | 2001-12-06 | 2009-12-24 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7273869B2 (en) | 2002-04-08 | 2007-09-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| WO2003086279A2 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003086403A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| MXPA04011093A (es) | 2002-05-10 | 2005-02-14 | Neurocrine Biosciences Inc | Piperazina sustituida como ligandos de receptores de melanocortina. |
| US7399764B2 (en) | 2002-10-30 | 2008-07-15 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| JP2006508974A (ja) | 2002-11-15 | 2006-03-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法 |
| WO2004048343A1 (en) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7638530B2 (en) | 2003-04-24 | 2009-12-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| AR045445A1 (es) | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
| JP2007501821A (ja) | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
| BRPI0414238A (pt) | 2003-09-09 | 2006-10-31 | Ono Pharmaceutical Co | antagonistas de crf e compostos heterobicìclicos |
| WO2005039564A1 (en) | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
| CN100594212C (zh) | 2003-10-21 | 2010-03-17 | 沃纳-兰伯特公司 | N-[(r)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯基氨基)-苯甲酰胺的多晶型物 |
| BRPI0416852A (pt) | 2003-11-21 | 2007-02-27 | Array Biopharma Inc | inibidores da quinase akt |
| DK1696920T3 (en) | 2003-12-19 | 2015-01-19 | Plexxikon Inc | RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS |
| WO2005094322A2 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| CN1972934A (zh) | 2004-06-28 | 2007-05-30 | 奥坦纳医药公司 | 4,6－二取代嘧啶及其作为蛋白激酶抑制剂的用途 |
| US20060025074A1 (en) | 2004-07-30 | 2006-02-02 | Chih-Ming Liang | Bluetooth-based headset |
| TWM266655U (en) | 2004-09-23 | 2005-06-01 | Blueexpert Technology Corp | Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal |
| TW200621257A (en) | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| EP1858902A1 (en) | 2005-02-24 | 2007-11-28 | Pfizer Products Incorporated | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| JP2008538102A (ja) | 2005-03-03 | 2008-10-09 | ザ バーナム インスティテュート フォー メディカル リサーチ | バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| RU2435769C2 (ru) | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| US20080004295A1 (en) | 2005-10-13 | 2008-01-03 | Gore Paul M | Novel compounds |
| WO2007060691A2 (en) | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | A novel process for the preparation of erlotinib |
| JP2009523701A (ja) | 2005-12-28 | 2009-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| US7814803B2 (en) | 2006-03-02 | 2010-10-19 | Nsk Ltd. | Torque sensor |
| EP2013206A1 (en) | 2006-04-25 | 2009-01-14 | Astex Therapeutics Limited | Pharmaceutical compounds |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| SI2049478T1 (sl) | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| PL2049500T3 (pl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| GB0613518D0 (en) | 2006-07-06 | 2006-08-16 | Phytopharm Plc | Chemical compounds |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| KR20090047509A (ko) | 2006-08-04 | 2009-05-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 유도체 및 이의 용도 |
| RS62034B1 (sr) * | 2006-08-25 | 2021-07-30 | Janssen Oncology Inc | Kompozicije za lečenje raka |
| US8828451B2 (en) | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
| CN101332301A (zh) * | 2007-06-26 | 2008-12-31 | 南京医科大学 | 一种抗肿瘤组合物及其应用 |
| EP2170062A4 (en) | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
| JP5568471B2 (ja) | 2007-07-12 | 2014-08-06 | ユニヴァーシティ オブ サウス フロリダ | 抗腫瘍活性を有するａｋｔ／ｐｋｂの阻害剤 |
| US8137919B2 (en) * | 2008-04-10 | 2012-03-20 | Montefiore Medical Center | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib |
| CN102105152B (zh) * | 2008-07-29 | 2012-10-17 | 内尔维阿诺医学科学有限公司 | 包含cdks抑制剂和抗肿瘤剂的治疗组合 |
| KR20110046514A (ko) * | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
| CA2831922C (en) | 2011-04-01 | 2019-12-31 | Genentech, Inc. | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
| EP2694959B8 (en) * | 2011-04-01 | 2019-12-25 | Genentech, Inc. | Biomarkers for predicting sensitivity to cancer treatments |
-
2012
- 2012-03-30 CA CA2831922A patent/CA2831922C/en active Active
- 2012-03-30 ES ES12764184.3T patent/ES2620644T3/es active Active
- 2012-03-30 SG SG10201504303SA patent/SG10201504303SA/en unknown
- 2012-03-30 LT LTEP12764765.9T patent/LT2694072T/lt unknown
- 2012-03-30 RU RU2013148721/04A patent/RU2013148721A/ru not_active Application Discontinuation
- 2012-03-30 WO PCT/US2012/031679 patent/WO2012135759A1/en not_active Ceased
- 2012-03-30 ES ES12765234.5T patent/ES2657750T3/es active Active
- 2012-03-30 DK DK12764765.9T patent/DK2694072T4/da active
- 2012-03-30 SG SG2013073788A patent/SG194052A1/en unknown
- 2012-03-30 CN CN201280026871.XA patent/CN103874689B/zh active Active
- 2012-03-30 MX MX2013011329A patent/MX2013011329A/es not_active Application Discontinuation
- 2012-03-30 EP EP12764765.9A patent/EP2694072B2/en active Active
- 2012-03-30 HU HUE12764765A patent/HUE036513T2/hu unknown
- 2012-03-30 TR TR2018/02093T patent/TR201802093T4/tr unknown
- 2012-03-30 WO PCT/US2012/031671 patent/WO2012135753A1/en not_active Ceased
- 2012-03-30 BR BR112013025353A patent/BR112013025353A8/pt not_active Application Discontinuation
- 2012-03-30 US US14/009,314 patent/US20150064171A1/en not_active Abandoned
- 2012-03-30 AU AU2012236144A patent/AU2012236144B2/en not_active Ceased
- 2012-03-30 JP JP2014502876A patent/JP6239497B2/ja active Active
- 2012-03-30 JP JP2014502873A patent/JP2014512354A/ja active Pending
- 2012-03-30 SG SG2013073747A patent/SG194048A1/en unknown
- 2012-03-30 BR BR112013025355-0A patent/BR112013025355B1/pt active IP Right Grant
- 2012-03-30 CN CN202110099289.7A patent/CN112915092A/zh active Pending
- 2012-03-30 US US14/009,310 patent/US9150548B2/en active Active
- 2012-03-30 MX MX2013011330A patent/MX351892B/es active IP Right Grant
- 2012-03-30 CN CN201280027028.3A patent/CN103635192B/zh active Active
- 2012-03-30 KR KR1020137029099A patent/KR20140025434A/ko not_active Withdrawn
- 2012-03-30 CN CN201410778065.9A patent/CN104586861A/zh active Pending
- 2012-03-30 SG SG2013073713A patent/SG194045A1/en unknown
- 2012-03-30 KR KR1020137029093A patent/KR101950044B1/ko not_active Expired - Fee Related
- 2012-03-30 FI FIEP12764765.9T patent/FI2694072T4/fi active
- 2012-03-30 US US14/009,316 patent/US9346789B2/en active Active
- 2012-03-30 BR BR112013025354A patent/BR112013025354A2/pt not_active IP Right Cessation
- 2012-03-30 PT PT127647659T patent/PT2694072T/pt unknown
- 2012-03-30 SI SI201231202T patent/SI2694072T2/sl unknown
- 2012-03-30 SM SM20180250T patent/SMT201800250T1/it unknown
- 2012-03-30 EP EP12765234.5A patent/EP2694485B1/en active Active
- 2012-03-30 MX MX2013011332A patent/MX354509B/es active IP Right Grant
- 2012-03-30 KR KR1020137029063A patent/KR102021157B1/ko not_active Expired - Fee Related
- 2012-03-30 WO PCT/US2012/031720 patent/WO2012135781A1/en not_active Ceased
- 2012-03-30 EP EP12764184.3A patent/EP2694071B1/en active Active
- 2012-03-30 KR KR1020137029130A patent/KR20140021646A/ko not_active Ceased
- 2012-03-30 RU RU2013148815A patent/RU2631240C2/ru active
- 2012-03-30 AU AU2012236138A patent/AU2012236138A1/en not_active Abandoned
- 2012-03-30 AU AU2012236166A patent/AU2012236166A1/en not_active Abandoned
- 2012-03-30 WO PCT/US2012/031665 patent/WO2012135750A1/en not_active Ceased
- 2012-03-30 BR BR112013025386-0A patent/BR112013025386B1/pt active IP Right Grant
- 2012-03-30 CN CN201280026870.5A patent/CN103841975A/zh active Pending
- 2012-03-30 MY MYPI2013003572A patent/MY179607A/en unknown
- 2012-03-30 RU RU2013148728/04A patent/RU2013148728A/ru not_active Application Discontinuation
- 2012-03-30 JP JP2014502886A patent/JP2014512356A/ja active Pending
- 2012-03-30 ES ES12764765T patent/ES2660263T5/es active Active
- 2012-03-30 CA CA2844699A patent/CA2844699C/en active Active
- 2012-03-30 CN CN201280026868.8A patent/CN103857395A/zh active Pending
- 2012-03-30 US US14/009,313 patent/US9150549B2/en active Active
- 2012-03-30 AU AU2012236135A patent/AU2012236135A1/en not_active Abandoned
- 2012-03-30 EP EP12763771.8A patent/EP2694070A4/en not_active Withdrawn
- 2012-03-30 JP JP2014502871A patent/JP6143739B2/ja active Active
- 2012-03-30 PL PL12765234T patent/PL2694485T3/pl unknown
- 2012-03-30 ME MEP-2018-22A patent/ME02998B/me unknown
- 2012-03-30 CN CN201710422676.3A patent/CN107233343A/zh active Pending
- 2012-03-30 RS RS20180052A patent/RS56759B2/sr unknown
- 2012-03-30 MX MX2013011327A patent/MX2013011327A/es not_active Application Discontinuation
- 2012-03-30 SG SG2013073770A patent/SG194051A1/en unknown
- 2012-03-30 CA CA2831937A patent/CA2831937A1/en not_active Abandoned
- 2012-03-30 RU RU2013148732/04A patent/RU2013148732A/ru not_active Application Discontinuation
- 2012-03-30 PL PL12764765.9T patent/PL2694072T5/pl unknown
- 2012-03-30 CN CN202010686337.8A patent/CN111643504A/zh active Pending
- 2012-03-30 HR HRP20180223TT patent/HRP20180223T4/hr unknown
- 2012-03-30 CA CA2831935A patent/CA2831935A1/en not_active Abandoned
-
2013
- 2013-09-30 IL IL228642A patent/IL228642A0/en unknown
- 2013-09-30 IL IL228641A patent/IL228641A0/en unknown
- 2013-09-30 IL IL228638A patent/IL228638A0/en unknown
- 2013-09-30 IL IL228637A patent/IL228637B/en active IP Right Grant
- 2013-10-29 ZA ZA2013/08064A patent/ZA201308064B/en unknown
- 2013-10-29 ZA ZA2013/08065A patent/ZA201308065B/en unknown
- 2013-10-29 ZA ZA2013/08062A patent/ZA201308062B/en unknown
- 2013-11-01 ZA ZA2013/08198A patent/ZA201308198B/en unknown
-
2015
- 2015-06-01 HK HK15105215.1A patent/HK1204575A1/xx unknown
- 2015-08-26 US US14/836,827 patent/US9610289B2/en active Active
-
2016
- 2016-02-05 US US15/017,315 patent/US9717730B2/en active Active
-
2017
- 2017-02-21 US US15/438,277 patent/US10092567B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509657A5 (OSRAM) | ||
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| US8383607B2 (en) | Perifosine and capecitabine as a combined treatment for cancer | |
| EP3923941A1 (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| JP7278331B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| CN103764144B (zh) | Pi3k抑制剂与mek抑制剂的协同组合 | |
| CN107250108A (zh) | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 | |
| JP2014512356A5 (OSRAM) | ||
| AU2012321110A1 (en) | Combination treatment | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2014512355A5 (OSRAM) | ||
| JP2025160200A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| CA2726644A1 (en) | Pharmaceutical combination comprising 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and pemetrexed, and use thereof in cancer treatment | |
| JP2016520662A (ja) | Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ | |
| JP6080837B2 (ja) | 療法的治療 | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP7707329B2 (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
| Schöffski et al. | Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer | |
| MX2013013406A (es) | Medicamentos y metodos para tratar cancer. | |
| Ang et al. | 393 POSTER First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies | |
| TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合 | |
| NZ619009B2 (en) | Medicaments and methods for treating cancer |